SJS Investment Consulting’s Candel Therapeutics CADL Stock Holding History

SJS Investment Consulting’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$961	Buy	+92	New	+$1.02K	﹤0.01%	2512

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return

ACPLP

ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

SJS Investment Consulting's CADL Position: Q3 2026 in Review

SJS Investment Consulting opened a new position in Candel Therapeutics (CADL) in Q3 2026: 92 shares worth $961. The stake represents ﹤0.01% of the portfolio and ranks #2512 among its holdings.

55 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

SJS Investment Consulting held 92 shares of Candel Therapeutics worth $961 as of Q3 2026.
Candel Therapeutics was a new SJS Investment Consulting position in Q3 2026.
Candel Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2512 holding.
55 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.